These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 18370488

  • 1. Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.
    Nannan Panday VR, van Warmerdam LJ, Huizing MT, Ten Bokkel Huinink WW, Vermorken JB, Giaccone G, Veenhof CH, Schellens JH, Beijnen JH.
    Clin Drug Investig; 1998; 15(4):327-35. PubMed ID: 18370488
    [Abstract] [Full Text] [Related]

  • 2. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula.
    Nagao S, Fujiwara K, Imafuku N, Kagawa R, Kozuka Y, Oda T, Maehata K, Ishikawa H, Koike H, Aotani E, Kohno I.
    Gynecol Oncol; 2005 Nov; 99(2):327-33. PubMed ID: 16005943
    [Abstract] [Full Text] [Related]

  • 3. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
    Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K.
    Cancer Chemother Pharmacol; 1998 Nov; 42(4):307-12. PubMed ID: 9744776
    [Abstract] [Full Text] [Related]

  • 4. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.
    Donahue A, McCune JS, Faucette S, Gillenwater HH, Kowalski RJ, Socinski MA, Lindley C.
    Cancer Chemother Pharmacol; 2001 May; 47(5):373-9. PubMed ID: 11391850
    [Abstract] [Full Text] [Related]

  • 5. Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance.
    White-Koning M, Paludetto MN, Le Louedec F, Gladieff L, Chevreau C, Chatelut E, Puisset F.
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):585-592. PubMed ID: 31915969
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.
    van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA, Beijnen JH.
    Cancer Chemother Pharmacol; 1996 Mar; 37(3):266-70. PubMed ID: 8529288
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate.
    Dooley MJ, Poole SG, Rischin D, Webster LK.
    Eur J Cancer; 2002 Jan; 38(1):44-51. PubMed ID: 11750838
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Evaluation of carboplatin dosing in non-small cell lung carcinoma patients using Calvert formula and Cockroft and Gault equation for glomerular filtration rate estimation.
    Bar-Sela G, Kaidar-Person O, Mari F, Assady S, Haim N.
    Oncol Lett; 2012 Nov; 4(5):1072-1076. PubMed ID: 23162654
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The use of the Calvert formula to determine the optimal carboplatin dosage.
    van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA, Beijnen JH.
    J Cancer Res Clin Oncol; 1995 Nov; 121(8):478-86. PubMed ID: 7642691
    [Abstract] [Full Text] [Related]

  • 16. Extension of the Calvert formula to patients with severe renal insufficiency.
    Oguri T, Shimokata T, Ito I, Yasuda Y, Sassa N, Nishiyama M, Hamada A, Hasegawa Y, Ando Y.
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):53-9. PubMed ID: 25957958
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P, Ortmanns P, Marien S, Degives R, Degraeve D, Potvin M, Grauwels D, Schallier D.
    Anticancer Res; 2001 Jul; 21(2B):1487-94. PubMed ID: 11396237
    [Abstract] [Full Text] [Related]

  • 20. A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party.
    Sculier JP, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V, Koumakis G, Lafitte JJ, Berchier MC, Alexopoulos CG, Zacharias C, Mommen P, Ninane V, Klastersky J.
    Eur J Cancer; 1999 Sep; 35(9):1314-9. PubMed ID: 10658520
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.